REFLECT

Clinical Trial

NCT03293524 Active, Not recruiting

REFLECT

Efficacy & Safety Study of Bilateral Intravitreal Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT).

Phase 3

Interventional

Disease

Disease type

Leber Hereditary Optic Neuropathy (LHON)

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

20/12/2018

Closing date

01/06/2024

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Main investigators

Pr Bart LEROY

Representative

Belgium

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Dr Catherine Vignal-Clermont

France

Neuro-Ophthalmology Rare Diseases (WG2)

Working Group Leader

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)